🔗 Permalink

Inventor profile of:

Dorthe Kot Engelund

City:

Holte

Country:

Denmark

Published Applications:

21

Last publication date:

2024-12-19

Top Assignees for applications by Dorthe Kot Engelund

The entities that hold a legal rights for patent applications filed by inventor Engelund Dorthe Kot:

Novo Nordisk A/S 15 Bagsvaerd, Denmark

Recent patent applications by Engelund Dorthe Kot

Dorthe Kot Engelund from Holte, DK has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-12-19

US20240415934A1

Human necessities

Stable Semaglutide compositions and uses thereof

#2 | 2023-11-16

US20230364241A1

Human necessities

PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES

#3 | 2023-03-23

US20230093542A1

Human necessities

GLP-1 COMPOSITIONS AND USES THEREOF

#4 | 2021-12-09

US20210379159A1

Human necessities

STABLE SEMAGLUTIDE COMPOSITIONS AND USES THEREOF

#5 | 2021-08-19

US20210252111A1

Human necessities

GLP-1 compositions and uses thereof

#6 | 2020-10-08

US20200316204A1

Human necessities

PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES

#7 | 2019-08-01

US20190231876A1

Human necessities

Propylene Glycol-Containing Peptide Formulations which are Optimal for Production and for Use in Injection Devices

#8 | 2018-04-19

US20180104335A1

Human necessities

Stable multi-dose compositions comprising an antibody and a preservative

#9 | 2018-01-04

US20180000935A1

Human necessities

Stable antibody containing compositions

#10 | 2013-05-30

US20130136733A1

Human necessities

Stable Multi-Dose Compositions Comprising an Antibody and a Preservative

#11 | 2013-01-31

US20130028907A1

Human necessities

Stable antibody containing compositions

#12 | 2012-09-06

US20120225810A1

Human necessities

PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES

#13 | 2010-09-16

US20100234299A1

Chemistry; metallurgy

Stable formulation of modified GLP-1

#14 | 2010-07-08

US20100173844A1

Human necessities

Stable formulations of peptides

#15 | 2009-11-19

US20090286716A1

Human necessities

Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia

#16 | 2009-04-30

US20090111752A1

Chemistry; metallurgy

Stable Formulation of Modified GLP-1

#17 | 2008-07-10

US20080167226A1

Chemistry; metallurgy

Stable formulation of modified GLP-1

#18 | 2008-05-29

US20080125361A1

Chemistry; metallurgy

Stable Formulations Of Peptides

#19 | 2007-01-11

US20070010424A1

Human necessities

Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices

#20 | 2006-12-21

US20060287221A1

Human necessities

Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia

#21 | 2006-04-20

US20060084605A1

Human necessities

Stable pharmaceutical compositions

InventorID:

65867 ⎘